1 / 7

EpiCast Report: Duchenne Muscular Dystrophy -Forecast 2020

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Identifying and Commercializing First-in-Class Innovation Detailed report at:

Download Presentation

EpiCast Report: Duchenne Muscular Dystrophy -Forecast 2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.


Presentation Transcript

  1. EpiCast Report: Duchenne Muscular Dystrophy - Epidemiology and Becker Muscular Dystrophy Forecast to 2020 Published By : GBI Research Published : May 2015

  2. Description Highly Innovative and Diverse Pipeline GBI Research analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products, acting on 13 first-in-class targets. The Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) pipeline consists of 84 molecules across all stages of development. Detailed report at: duchenne-muscular-dystrophy-and-becker-muscular-dystrophy-identifying-and- commercializing-first-in-class-innovation-market This exceptional first-in-class innovation is largely due to the high number of first- in-class products solely targeting the dystrophin gene, which is the primary genetic cause of DMD and BMD. The strong presence of first-in-class products in the pipeline therefore creates a distinctly different landscape to the market landscape, which relies on symptomatic treatment glucocorticoids.

  3. Description Despite a strong focus on personalized treatments that treat the genetic cause of the disease in the DMD/BMD pipeline, innovation is also concentrated on novel molecular targets that alleviate the dystrophic pathology regardless of gene mutations, thereby allowing widespread use in contrast to the mutation- specific treatments. These therapies are expected to be used alongside primary treatment to repair the mutated gene, halt muscle degeneration, and improve life expectancy of patients in the future market. Strong Alignment of Innovation to Genetics and Disease Processes in Early Pipeline Analysis also indicates opportunities for some of the first-in-class DMD/BMD targets to be repositioned to other MDs, although this is expected to be challenging given the currently limited understanding of the common molecular processes defected across multiple types of MD.

  4. Description Numerous Investment Opportunities in Deals Landscape Strategic consolidation is relatively uncommon in the DMD/BMD market, with 15 licensing agreements and 18 co-development deals between 2006 and April 2015. Supported by findings from the industry-wide analysis, there is a tendency for first-in-class DMD programs to attract higher deal values than non-first-in- class programs, thus highlighting their commercial attractiveness. With 36 first-in-class products that are currently in development having not yet been involved in a licensing or co-development deal, there are numerous opportunities for in-licensing or co-development in this indication. Web link:

  5. Table of Contents  1 Table of Contents 1.1 List of Tables 1.2 List of Figures  2 Executive Summary 2.1 Biologics Growing in Prominence in Asthma Treatment  3 The Case for Innovation in Asthma 3.1 Growing Number of Opportunities for Biologic Products  4 Clinical and Commercial Landscape 4.1 Disease Overview  5 Assessment of Pipeline Product Innovation 5.1 Asthma Pipeline by Phase, Molecule Type and Therapeutic Target

  6. Table of Contents  6 Signaling Network, Disease Causation and Innovation Alignment  7 First-in-Class Target and Pipeline Program Evaluation  8 Deals and Strategic Consolidations  9 Appendix 62 For inquiry, kindly contact at: To check table of contents of the research, Visit @: muscular-dystrophy-and-becker-muscular-dystrophy-identifying-and- commercializing-first-in-class-innovation-market/table-of-contents

  7. FOR MORE DETAILS Visit us at : muscular-dystrophy-and-becker-muscular-dystrophy-identifying-and- commercializing-first-in-class-innovation-market Stay With Us: TELEPHONE: Direct: +1 (617) 674-4143 Toll Free: +1 (855) 711-1555 E-MAIL: 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States

More Related